Today's Top Biotech Stocks: Bristol-Myers Squibb, United Therapeutics and Vertex Pharmaceuticals

Today's top stories in health care and biotech.

Jun 27, 2014 at 9:11AM

LongviewEditor's Note: An earlier version of this article included the ticker VRX with Vertex Pharmaceuticals (Vertex's ticker is VRTX). The Fool regrets the error.

Let's take a look at today's top stories in biotech and health care. Keep an eye out for Bristol-Myers Squibb (NYSE:BMY), United Therapeutics (NASDAQ:UTHR) and Vertex Pharmaceuticals (NASDAQ:VRTX).  

Bristol-Myers is a fountain of good news this morning
Shares of Bristol-Myers should move higher today following two pieces of good news on the regulatory front in the EU. First off, the company announced that its pan-genotypic NS5A inhibitor Daklinza received a positive opinion from the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency. The drug has been studied as part of an all-oral combo therapy with Gilead Sciences' Sovaldi, where it produced strong efficacy results and a similar safety profile compared to currently approved therapies. 

In a separate announcement, the company said that its oral anticoagulant Eliquis has been recommended for treating deep vein thrombosis, pulmonary embolism, and in the prevention of recurrent cases. Eliquis is co-owned by Pfizer (NYSE:PFE) and is expected to compete in a broad market of next generation blood thinners that could see combined sales of $10 billion within the next few years. 

United Therapeutics to buyback $500 million worth of common stock
United Therapeutics could be in for a good day after announcing an additional $500 million worth of share buybacks set to commence on Aug 1 of this year. According to the release, the purchase period will be 1 year in duration. United recently completed a repurchase program where it bought $4.6 million of its own shares, so this new program is a major step up in terms of its buyback program.

United's share price has a tough go of it this year, falling 22% year to date. What's interesting is that this drop has occurred despite rising revenues from key products like Remodulin and Tyvaso. Put simply, today's large share buyback program suggests that the company believes in their growth prospects moving forward and the current share price represents a compelling valuation scenario. So you may want to keep a close watch on this mid-cap drugmaker.  

Vertex moving higher today on label expansion for Kalydeco
Shares of Vertex Pharmaceuticals are up nearly 4% in premarket this morning following a positive opinion from the CHMP for Kalydeco as a treatment for people with cystic fibrosis who have one of eight non-G551D gating mutations in the cystic fibrosis, or CF, transmembrane conductance regulator gene.

Put simply, an approval would expand the drug's use to include an additional 8 gating mutations that cause CF. Kalydeco was first approved in 2012 as a treatment for CF in people with the G551D mutation and saw sales of $100 million in the first-quarter of this year for this indication. Given that a major label expansion like this one should translate into higher top-line growth moving forward, I think Vertex is a stock worth putting on your watchlist. 
 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

 

George Budwell owns shares of Isis Pharmaceuticals. The Motley Fool recommends Gilead Sciences and Isis Pharmaceuticals. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.

 


Compare Brokers